| ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing (NCT05380557) | Invitae Corporation | 2021-08-23 |
| Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer (NCT03718650) | H. Lee Moffitt Cancer Center and Research Institute | 2021-04-01 |
| Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy (NCT04810910) | Zhejiang Provincial People's Hospital | 2021-03-30 |
| GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NCT04472910) | University Health Network, Toronto | 2020-08-21 |
| Intraoperative Radiation Therapy for Resectable Pancreatic Cancer (NCT05181488) | Yona Cho | 2020-04-02 |
| Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study (NCT04737551) | Shanghai Zhongshan Hospital | 2020-01-01 |
| Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer (NCT03492671) | Loma Linda University | 2019-07-17 |
| Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients (NCT03392571) | Pancreatic Cancer Research Team | 2018-08-15 |
| Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer (NCT03435536) | University Hospital, Toulouse | 2018-02-26 |
| Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma (NCT03822936) | CNAO National Center of Oncological Hadrontherapy | 2018-02-08 |
| Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (NCT03138720) | HonorHealth Research Institute | 2017-05-23 |
| Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer (NCT02775695) | Medical College of Wisconsin | 2017-04-03 |
| A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer (NCT06363084) | Ruijin Hospital | 2016-05-01 |
| Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (NCT02345460) | Case Comprehensive Cancer Center | 2015-09-01 |
| Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer (NCT02243007) | Massachusetts General Hospital | 2014-09-01 |
| EUS vs. MDCT in Pancreatic Malignancy (NCT02115022) | Clinical Hospital Colentina | 2014-07-01 |
| Borderline Pancreas Study: FOLFIRINOX +SBRT (NCT01992705) | University of Maryland, Baltimore | 2014-03-01 |
| A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer (NCT01694589) | Rutgers, The State University of New Jersey | 2012-11-01 |
| Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer (NCT01298011) | Pancreatic Cancer Research Team | 2011-05-01 |